

## Protein Sciences Launches Social Media Campaign for Flublok® Influenza Vaccine to Raise Money for Health-based Charities

---

### **For Immediate Release**

October 20, 2016

### **Contact:**

Courtney Reis  
Communications Associate  
Phone: (203) 686-0800 ext. 301

**Meriden, CT** —[Protein Sciences Corporation](#) proudly announced the launch of a new social media campaign - #ShowMeTheVial - featuring [Flublok® influenza vaccine](#) that will raise money for health-based charities. Flu vaccination is known to be especially beneficial to individuals with underlying health problems, such as heart disease, cancer, diabetes, obesity and other conditions that generally weaken the immune system. These individuals are at greatest risk for developing complications from the flu that can lead to hospitalization and even death. To promote awareness and healthy living, raise money for organizations supporting patients with these diseases, and encourage individuals to ask for Flublok, Protein Sciences will donate money to charity each time someone “shows them the [Flublok] vial”. In addition, participants will be entered to win a Fit & Healthy prize package that includes a new Fitbit Blaze.

How it works: social media users nationwide are asked to post a photograph of themselves receiving Flublok (note it must be Flublok and not another flu vaccine) with the hashtag “#ShowMeTheVial” and/or “#FlublokProtected on Facebook, Twitter or Instagram. For each post, Protein Sciences will donate \$1 to a health-based charity. First up is the American Heart Association. Participants will also have their name entered 5 times per post for a chance to win the prize package. People can also be entered to win the prize package by sharing any #ShowMeTheVial or #FlublokProtected post on any of their social media channels; each share gets a person one entry into the prize drawing. A winner will be named at the end of the flu season on April 30<sup>th</sup>, 2017.

“Flublok ambassadors are everywhere and we’d like to recognize the passion they show for our product,” said Manon Cox, President and CEO of Protein Sciences Corporation. “This is our way of giving back to them and to an important cause. Many people still don’t realize they have a choice in flu vaccines, and we hope this campaign will help educate people about Flublok.”

Flublok is currently available at hundreds of pharmacies across the United States. To find the closest location to you, visit their [Flublok Finder](#) today. If you still have difficulty finding a location close to you, please contact Protein Sciences directly by calling them at the phone number listed below.

For more information about Flublok, please visit [www.flublok.com](http://www.flublok.com).

## About Protein Sciences

Protein Sciences specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals.

## About Flublok

Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, was initially approved by the U.S. FDA in January 2013. FDA expanded its approval in October 2014 to include everyone over 18 years, approved a nine month shelf life in June 2016, and approved a quadrivalent formulation in October 2016. Flublok is also licensed for sale in Mexico and licensure in additional countries, including Japan, is expected in the near future. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus, antibiotics or harsh chemicals in manufacturing. Flublok is highly purified and does not contain any preservatives (e.g., thimerosal, which contains mercury), egg proteins, gelatin or latex. In addition, Flublok contains three times more antigen than traditional flu vaccines (3x45mcg hemagglutinin protein versus 3x15mcg hemagglutinin protein).\* In a 2014/15 post-marketing study of 9,000 adults 50 years and older, people who received Flublok were over 40% less likely to get cell culture confirmed influenza than people who received a traditional flu vaccine. Flublok is an accurate copy of the virus coat and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see [Skowronski et al. \(2014\) PLOS ONE 9\(3\), e92153](#)).

Healthcare professionals wishing to order Flublok should contact one of the following distributors:

- Protein Sciences Corporation: 203-686-0800 [www.flublok.com](http://www.flublok.com)
- FFF Enterprises: 800-843-7477 [www.myfluvaccine.com](http://www.myfluvaccine.com)
- Cardinal Health: 866-677-4844 <http://www.cardinal.com/flu>
- McKesson: 877-MCK-4FLU [mms.mckesson.com](http://mms.mckesson.com)
- Moore Medical: 800-234-1464 [www.mooremedical.com/flu](http://www.mooremedical.com/flu)
- Henry Schein: 1-800-772-4346 [www.henryschein.com](http://www.henryschein.com)

Learn more at [www.proteinsciences.com](http://www.proteinsciences.com) and [www.flublok.com](http://www.flublok.com).

## Flublok Safety Information

Flublok is approved for people 18 and older to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Headache, fatigue or muscle ache may occur. Tell the doctor if you have ever experienced Guillain-Barré syndrome (severe muscle weakness) or have had a severe allergic reaction to any component of Flublok vaccine. Vaccination with Flublok may not protect all individuals. Please see the complete Package Insert available at [www.flublok.com](http://www.flublok.com) or call 203-686-0800 for more information.

\*Flublok demonstrated a higher antibody response to the A strains in two field trials in adults ≥50 years old. The B strain antibody responses were comparable to traditional trivalent and quadrivalent vaccines.

###